Charles Ellis
Last active: 9/24/2018

Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients.

Hung AM, Limkunakul C, Placido JS, Siew ED, Ellis CD, Shintani A, Ikizler TA
J Nephrol. 2014 27 (6): 681-8

PMID: 24609887 · DOI:10.1007/s40620-014-0070-3

BACKGROUND - Adiponectin, an adipose tissue derived hormone, is known to have insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties in the general population. Adiponectin secretion is suppressed by systemic inflammation, a highly prevalent condition in maintenance hemodialysis (MHD) patients. We evaluated whether short-term administration of interleukin 1 receptor antagonist (IL-1ra) improves adiponectin levels and insulin sensitivity in MHD patients.

METHODS - Ad hoc analysis was performed on a pilot randomized placebo-controlled trial of the administration of IL-1ra in chronically inflamed MHD patients. Twenty-two patients were randomly assigned to receive 100 mg of IL-1ra or placebo (1:1) for 4 weeks, and 14 completed the trial. ANCOVA was used to compare percent change from baseline to 4 weeks. The primary outcome was percent change in adiponectin and the secondary outcomes were changes in leptin, homeostatic model assessment of insulin resistance (HOMA-IR) and the leptin-to-adiponectin ratio (LAR).

RESULTS - Patients' mean age was 49 ± 13 years, and 71 % were males. At baseline, the median values for adiponectin, leptin, LAR and HOMA-IR were 11.5 μg/ml [interquartile range (IQR) 9, 28.5], 17.8 ng/ml (3.9, 50.0), 2.20 (0.13, 3.98), and 2.8 (2.0, 3.6), respectively. IL-1ra administration resulted in a mean percent increase in serum adiponectin of 22 % vs. 14 % decrease in the placebo arm (p = 0.003). Leptin, LAR or HOMA-IR levels did not change in either arm.

CONCLUSIONS - Short-term administration of IL-1ra significantly increased adiponectin levels among prevalent MHD patients. The intervention did not impact insulin sensitivity parameters. Studies of longer duration and larger sample size are needed to further evaluate the potential effect of anti-inflammatory interventions on metabolic markers and insulin sensitivity in MHD patients.

MeSH Terms (20)

Adiponectin Adult Aged Anti-Inflammatory Agents Biomarkers Female Humans Inflammation Insulin Resistance Interleukin 1 Receptor Antagonist Protein Leptin Male Middle Aged Pilot Projects Renal Dialysis Renal Insufficiency, Chronic Tennessee Time Factors Treatment Outcome Up-Regulation

Connections (4)

This publication is referenced by other Labnodes entities: